biotech / news / / The Manila Times
For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate.
Insilico Medicine nominated ISM0387, the UAE's first locally discovered AI-designed preclinical drug candidate.
KEY POINTS
- ISM0387 is an MTA-cooperative PRMT5 inhibitor optimized for brain penetration and glioblastoma treatment.
- The full discovery process for ISM0387, from molecular design to nomination, was conducted within the UAE in under 12 months.
- Using Chemistry42 and 40+ AI models, Insilico discovered and optimized ISM0387 by screening 90 novel compounds, completing lead discovery in six months.
- Enhanced blood-brain barrier penetration and robust efficacy were confirmed for ISM0387 in cancer models, supporting future clinical potential.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →